A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge.
Hansen SG, Marshall EE, Malouli D, Ventura AB, Hughes CM, Ainslie E, Ford JC, Morrow D, Gilbride RM, Bae JY, Legasse AW, Oswald K, Shoemaker R, Berkemeier B, Bosche WJ, Hull M, Womack J, Shao J, Edlefsen PT, Reed JS, Burwitz BJ, Sacha JB, Axthelm MK, Früh K, Lifson JD, Picker LJ.
Hansen SG, et al.
Sci Transl Med. 2019 Jul 17;11(501):eaaw2607. doi: 10.1126/scitranslmed.aaw2607.
Sci Transl Med. 2019.
PMID: 31316007
Free PMC article.